Pre-Made Taldefgrobep Alfa Biosimilar, Fusion Protein targeting MSTN/GDF-8 fused with human IGHG1 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting GDF8/MSLHP for drug discovery and mechanism of action (MOA) research

Pre-Made Taldefgrobep Alfa Biosimilar, Fusion Protein targeting MSTN/GDF-8 fused with human IGHG1 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting GDF8/MSLHP is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Taldefgrobep alfa is a Immunoglobulin g1 (human fc fragment) fused with adnectin, anti-(human growth differentiation factor 8) (human clone bms-986089 fibronectin tenth type iii domain-derived), dimer. Taldefgrobep alfa is a modified adnectin designed to specifically bind to myostatin (GDF-8). Adnectins is a therapeutic class based human fibronectin, an extracellular protein that is naturally abundant in human serum. Taldefgrobep alfa used for the treatment of neurologic, neuroinflammatory, and neuropsychiatric disorders.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-1004-1mg	1mg	3090
GMP-Bios-INN-1004-10mg	10mg	Inquiry
GMP-Bios-INN-1004-100mg	100mg	Inquiry
GMP-Bios-INN-1004-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Taldefgrobep Alfa Biosimilar, Fusion Protein targeting MSTN/GDF-8 fused with human IGHG1 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting GDF8/MSLHP
INN Name	Taldefgrobep Alfa
Target	MSTN/GDF-8
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	Fusion - IGHG1 Fc (Fragment constant) - [peptidyl linker - Alternative to antigen receptors (domain scaffold: FN1 F10, fibronectin domain F10)]2
VD LC	Fusion - IGHG1 Fc (Fragment constant) - [peptidyl linker - Alternative to antigen receptors (domain scaffold: FN1 F10, fibronectin domain F10)]2
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Bristol-Myers Squibb (Princeton NJ USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	Alternative to antigen receptors, domain scaffold FN1 F10, fibronectin F10 (Adnectin™)